Literature DB >> 18096762

Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients.

Hermann Brenner1, Adam Gondos, Dianne Pulte.   

Abstract

Since the breakthroughs in combination chemotherapy of patients with Hodgkin disease (HD) starting in the 1960s, prognosis of patients has been rising steadily. Trends in long-term survival of patients with HD on the population level should therefore be monitored in an as timely as possible manner. We assessed trends in age specific 5- and 10-year relative survival of patients with HD in the United States from 1980-1984 to 2000-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Period analysis was used to disclose recent developments with minimum delay. Overall, 5-year relative survival steadily increased from 73.5% to 85.2% (+11.7 percentage units), and 10-year relative survival increased from 62.1% to 80.1% (+18.0 percentage units) between 1980-1984 and 2000-2004, according to period analysis. The increase was particularly pronounced for patients aged 45 to 59 years and 60 years and older (increases in 10-year relative survival by 24.8 and 23.3 percentage points, respectively). Nevertheless, a strong age gradient persisted, with 10-year relative survival of 92.7%, 88.7%, 84.9%, 76.2%, and 44.9% in patients aged 15 to 24 years, 25 to 34 years, 35 to 44 years, 45 to 54 years, and 60 years and older, respectively, in 2000-2004. Our period analysis discloses ongoing, major improvement in long-term survival of patients with HD in recent years, particularly among older patients.

Entities:  

Mesh:

Year:  2007        PMID: 18096762     DOI: 10.1182/blood-2007-10-115493

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study.

Authors:  Elena B Elkin; Michelle L Klem; Anne Marie Gonzales; Nicole M Ishill; David Hodgson; Andrea K Ng; Lawrence B Marks; Joanne Weidhaas; Gary M Freedman; Robert C Miller; Louis S Constine; Sten Myrehaug; Joachim Yahalom
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

3.  Long-term follow-up after childhood cancer in France supported by the SFCE-force and weakness-current state, results of a questionnaire and perspectives.

Authors:  Charlotte Demoor-Goldschmidt; Marie-Dominique Tabone; Valérie Bernier; Florent de Vathaire; Claire Berger
Journal:  Br J Radiol       Date:  2018-01-10       Impact factor: 3.039

Review 4.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

Review 5.  Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.

Authors:  Neha Mehta-Shah; Nancy L Bartlett
Journal:  Blood       Date:  2018-03-02       Impact factor: 22.113

6.  Successful transcatheter aortic valve implantation in a Hodgkin lymphoma patient with severe aortic stenosis.

Authors:  Cenk Sari; Tahir Durmaz; Abdullah Nabi Aslan; Telat Keleş; Murat Akçay; Nihal Akar Bayram; Hüseyin Ayhan; Emine Bilen; Serdal Baştuğ; Haci Ahmet Kasapkara; Mehmet Burak Özen; Ömer Faruk Çiçek; Engin Bozkurt
Journal:  Int J Hematol       Date:  2014-01-31       Impact factor: 2.490

7.  Management of older Hodgkin lymphoma patients.

Authors:  Andrew M Evens; Jordan Carter; Kah Poh Loh; Kevin A David
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Caecal leiomyoma detected by whole-body MRI in a patient with Hodgkin lymphoma: first case report.

Authors:  D Albano; E Sinagra; C Patti; D Narese; A Agrusa; G Di Buono; D Raimondo; M Midiri; R Lagalla; M Galia
Journal:  G Chir       Date:  2017 Jan-Feb

9.  Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.

Authors:  Ana C Xavier; Narendranath Epperla; Jeffrey W Taub; Luciano J Costa
Journal:  Am J Hematol       Date:  2017-11-21       Impact factor: 10.047

10.  The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Authors:  Andrew M Evens; Fangxin Hong; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D Cheson; Patrick J Stiff; Ranjana Advani; Thomas P Miller; Richard T Hoppe; Brad S Kahl; Sandra J Horning
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.